Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA, Amarin to Settle on Off-Label Drug Marketing

By Drug Discovery Trends Editor | March 9, 2016

The U.S. Food and Drug Administration and drug company Amarin announced late Tuesday the proposed settlement terms of a lawsuit about off-label drug promoting: Amarin will be allowed to market its fish-oil product, Vascepa (icosapent ethyl), for unapproved indications.

According to the settlement, the FDA will not appeal a previous court ruling in Amarin’s favor, which said that Amarin is free under the First Amendment to disseminate truthful information to promote its drug, even if it’s for unapproved uses.

Vascepa is currently approved by the FDA to reduce triglycerides in adults with severely elevated levels. Dublin-based Amarin has been seeking the right to send physicians promotional materials about research suggesting that the drug reduces cardiovascular event risk.

Amarin said it remained committed to completing an ongoing clinical trial, REDUCE-IT, in hopes that it will prove that benefit.

“With more truthful and non-misleading information readily available to healthcare professionals about the potential of Vascepa to improve cardiovascular health, this settlement serves the public interest by supporting informed medical decisions for tens of millions of patients with persistent high triglycerides,” John Thero, president and CEO of Amarin, said in a prepared statement.

The FDA said in a statement that the settlement applied only to the Amarin case — and that the agency’s position on whether pharmaceutical companies have a constitutional right to provide “non-misleading information” to promote off-label use has not changed.

However, some experts are saying the settlement could set a dangerous precedence, in allowing other drug makers to seek similar arrangements to promote their products for unapproved uses.

Read the New York Times article.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE